Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

folate receptor-targeted tubulysin conjugate EC1456

An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:folate receptor-targeting folate-tubulysin conjugate EC1456
Code name:EC1456
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search